On August 22, Iovance Biotherapeutics, Inc. declined 8.06% in regular trading, trading at $8.2842/share, with turnover of $176 million. The pullback follows a UBS Securities report highlighting competitive risks facing the company's core product.

UBS issued a research note stating that Amtagvi, Iovance's autologous cell therapy for advanced melanoma, faces mounting competitive pressure from emerging melanoma therapies and prolonged onboarding timelines at authorized treatment centers, often exceeding six months. Despite Q2 Amtagvi revenue of $91 million surpassing UBS's $80 million estimate, the bank maintained a neutral rating and raised its price target from $4 to $7, still well below the analyst consensus mean of $9.33. UBS forecasts Q3 Amtagvi revenue of approximately $96 million and full-year total revenue of $405 million, but cautioned that the evolving competitive landscape could continue to pressure growth prospects.

The decline reverses part of the gains accumulated since the company reported record Q2 revenue of approximately $99 million on August 6, which had significantly exceeded the $87.83 million consensus estimate.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)